Catalyst Wire Dossier Catalyst Wire Dossier

Ibrexafungerp

ibrexafungerp · Scynexis, Inc.
Drug timelines are a Plus or Pro feature.

8 regulatory and trial events tracked for Ibrexafungerp, covering 2021-09-08 to 2026-08-10. Get the full timeline:

Most recent: Clinical Trial Results: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole [Phase 3]

See pricing